T1	Participants 245 400	patients with severe aplastic anemia (SAA) treated with anti-lymphocyte globulin (ALG), cyclosporin (CyA) and granulocyte colony-stimulating factor (G-CSF)
T2	Participants 725 850	ulticenter prospective trial in 77 SAA patients treated with horse ALG (15 mg/kg/day day1-5) and CyA (5 mg/kg/day day 1-180).
T3	Participants 2085 2124	patients with SAA receiving ALG and CyA
